How will abstracts be presented?
Accepted abstracts will be presented as posters at the congress.
How will abstracts be published?
All accepted abstracts have been published in a congress supplement to Kidney International Reports which can be found here.
Poster Upload
E-poster upload must be done no later than February 5, 2022. After this date you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible in the virtual Poster Area. Please see here for all requirements and for the upload procedure.
Late-Breaking Abstracts
Late-breaking abstracts cover ground-breaking data that would not otherwise have been presented at WCN’22. If such data are available after the regular abstract deadline, the Scientific Program Working Group will still consider it for presentation.
Late-breaking abstracts describe the latest advances, trial data, and results that have not been previously published or presented and highlight novel and practice-changing studies.
Select late-breaking abstracts have been accepted to present at WCN’22 during the Late Breaking Clinical Trials session.
Embargo Policy
For abstracts accepted for presentation and publication during WCN’22, the following embargo policy applies.
WCN’22 Embargo Policy
Explore abstract categories below:
Chronic kidney disease, hypertension, diabetes and CVD
- Chronic kidney disease complications (CVD, hypertension, anemia, BMD, nutrition, infection)
- Chronic kidney disease diagnosis, classification and progression
- Chronic kidney disease, experimental models, biomarkers, precision medicine
- Diabetic kidney disease, drugs and treatments
- Epidemiology, outcomes and health service research related to CKD or its complications
- Essential hypertension and renovascular kidney disease
- Genetics and epigenetics (including common and rare genetic diseases)
- Inflammation, fibrosis, matrix biology and oxidative stress
- Nephrotic syndrome
- Physiology of tubular function and tubulointerstitial kidney disease
- Special challenges in the burden and management of CKD in developing countries
- Urologic disorders –stones, nephrocalcinosis
- Vascular biology and endothelial function
- Other CKD
AKI, electrolytes, acid-base disorders, tropical diseases, RPGN and pregnancy
- Acid-base and electrolyte abnormalities in kidney disease
- Acute kidney injury – mechanisms, experimental models and biomarkers
- Acute kidney injury clinical, drugs, AKI-CKD continuum
- Clinical glomerulonephritis
- Experimental models- glomerulonephritis
- Kidney in pregnancy and post-partum
- Tropical kidney diseases (viral nephropathies, TB, schistosomiasis, malaria, leptospirosis, animal venoms)
- Other AKI
Kidney Failure (Former ESKD), Including Dialysis, Transplantation, Conservative Care
- Bioethics, supportive/palliative care and quality of life in Kidney Failure (former ESKD)
- Epidemiology, outcomes and health services research in dialysis
- Haemodialysis, haemodiafiltration and vascular access
- Kidney transplantation and transplant immunology
- Other Kidney Failure (Former ESKD)
- Peritoneal dialysis
Education
- Training
- Social media
- Curriculum
- Online learning
Special Covid-19
- Covid-19 and AKI
- Covid-19 and CKD
- Covid-19 and ESKD